Several clinical studies reveal that semaglutide proves to be an extremely effective drug for weight control. It is approved for weight management in patients with diabetes. It contains glucose-reducing components and is therefore effective in reducing glucose levels after a meal. Its mechanism of action is unknown in both the studies.
In June 2021, Novo Nordisk A/S completed a study that investigated the effectiveness of once-weekly subcutaneous semaglutide in a real world adult population with type 2 diabetes in Germany. The U.S. Food and Drug Administration later approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. According to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Such high prevalence of diabetes is expected to boost demand for Semaglutide.
Because of the potential risk for complications of complications, patients should discuss the intended course of action with their doctor prior to beginning any new medications. Patients should inform their doctor of their intent to start taking Semaglutide and they should be advised of the possible outcomes of this course of action. If these discussions are handled the way the professional caregivers suppose they should then the drug semaglutide may have no undesirable outcome. However, the patient must be honest about their intention to their doctor and they should inform their doctor of all medications they are currently taking other than Ozempic and of any medical conditions they may be suffering from. This way, the professional caregiver will be made aware of any adverse reactions that could occur.
No comments:
Post a Comment